Fort Worth, TX – According to filings with the U.S. Securities and Exchange Commission, Actuate Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Daniel Schmitt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Actuate Therapeutics

Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis. Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3, based on intellectual capital developed in the laboratories of Dr. Alan Kozikowski at the University of Illinois-Chicago and the Center for Developmental Therapeutics at Northwestern University. The company is led by a senior management and scientific team with decades of pharmaceutical industry experience leading successful discovery, development, and commercialization of new therapeutic agents and health related technologies.

To learn more about Actuate Therapeutics, visit http://actuatetherapeutics.com/

Contact:
Daniel Schmitt, President and Chief Executive Officer
847-986-4190
dschmitt@actuatetherapeutics.com
https://www.linkedin.com/in/dan-schmitt-0094b05/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved